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Introduction: The maximum standardized uptake value (SUVmax) 
on 18F-ﬂuorodeoxyglucose positron emission tomography is a predic-
tor for overall survival (OS) in non–small-cell lung cancer (NSCLC) 
after resection. We investigated the association between SUVmax 
and outcomes in NSCLC after stereotactic body radiotherapy.
Methods: Between 2005 and 2012, 283 patients with early NSCLC 
(T1a-2N0M0) were treated with stereotactic body radiotherapy; the 
total doses were 40 to 60 Gy in five fractions. Patients who under-
went staging 18F-ﬂuorodeoxyglucose positron emission tomography 
scans by a single scanner and were followed up for more than or who 
died within 6 months were eligible. The optimal threshold SUVmax 
was calculated for each outcome. Outcomes were analyzed using the 
Kaplan–Meier method and log-rank test. Prognostic significance was 
assessed by univariate and multivariate analyses.
Results: One hundred fifty-two patients were eligible. Median 
follow-up was 25.3 (range, 1.3–77.4) months. Local, regional, 
and distant recurrences, cancer-specific deaths, and deaths from 
other reasons occurred in 14, 11, 27, 21, and 31 patients, respec-
tively. The optimal threshold SUVmax for local, regional, and dis-
tant recurrences, and disease-free survival (DFS), cancer-specific 
survival, and OS were 2.47 to 3.64. Outcomes of patients with 
SUVmax lower than each threshold were significantly better than 
those with higher SUVmax (all p<0.005): 3-year DFS rates were 
93.0% versus 58.3% (p<0.001) and 3-year OS rates were 86.5% 
versus 42.2% (p<0.001), respectively. By multivariate analy-
sis, higher SUVmax was a significantly worse predictor for DFS 
(p<0.01) and OS (p=0.04).
Conclusions: SUVmax was a predictor for DFS and OS. A high 
SUVmax may be considered for intensive treatment to improve 
outcomes.
Key Words: 18F-ﬂuorodeoxyglucose positron emission tomography, 
Stage I non–small-cell lung cancer, Stereotactic body radiotherapy.
(J Thorac Oncol. 2014;9: 65–73)
For non–small-cell lung cancer (NSCLC), prognosis and therapy have been guided chieﬂy by the Tumor Node 
Metastasis staging system. Although stage I NSCLC patients 
have the best prognosis, their 5-year survival rate is approxi-
mately 60%.1 Recently, 18F-ﬂuorodeoxyglucose (FDG) posi-
tron emission tomography (PET) imaging is widely used to 
determine Tumor Node Metastasis stage in NSCLC patients 
and is altering the stage designation and management in as 
many as 20% to 40% of patients.2 A systematic review of 
resection in stage I NSCLC patients revealed that increased 
tumor FDG uptake is associated with worse survival.3 These 
results suggest that FDG uptake can provide additional infor-
mation about the biological characteristics of tumors that 
cannot be obtained by morphological imaging tests such as 
computed tomography (CT), and that it may be a potential 
biomarker for identifying stage I NSCLC patients with a high 
risk of recurrence or death.
Currently, stereotactic body radiation therapy (SBRT) 
is considered as a treatment option for patients with medi-
cally inoperable early-stage NSCLC.4 We previously reported 
that maximum standardized uptake value (SUVmax) of pri-
mary tumors was a predictor for local control in NSCLC 
after SBRT.5 In this study, herein we retrospectively inves-
tigated whether the SUVmax was a predictor for outcomes 
including disease-free survival (DFS) and overall survival 
(OS) after SBRT.
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PATIENTS AND METHODS
Patients
From November 2005 through July 2012, 283 patients 
with early NSCLCs (T1a-2N0M0) and Eastern Cooperative 
Oncology Group performance status 0 to 2 were treated 
with SBRT: the total doses of 40 to 60 Gy in five fractions 
with radical intent. These patients had been diagnosed 
with NSCLC based on the following clinical findings: high 
SUVmax on FDG-PET scan, continuous tumor growth and 
characteristic findings on CT images and/or increases in 
tumor markers such as carcinoembryonic antigen, carbo-
hydrate antigen 19-9, sialyl Lewis X-i antigen, squamous 
cell carcinoma  antigen and cytokeratin 19 fragment. These 
diagnoses were completed after reaching a consensus among 
radiation oncologists, diagnostic radiologists, thoracic sur-
geons, and pulmonologists. Reasons for unproven histol-
ogy included failed pathological studies, increased risk of 
hemorrhage during biopsy, patients’ refusals, or technical 
difficulties during biopsy attempt. Among all 283 patients, 
235 (83.0%) underwent 18F-FDG-PET scans for staging 
before treatment. For this study, eligible patients underwent 
18F-FDG-PET scans before treatment by a single scanner at 
Yuai Clinic. Those who were lost to follow-up during the 
6 months after treatment were excluded from the present 
analysis, except for patients who died.
This retrospective study was approved by the ethics 
committee at our institution (No. 2010-005). Written informed 
consent was obtained from patients for the staging tests, treat-
ment, and follow-up studies.
FDG-PET and Data Analysis
Each patient underwent FDG-PET before SBRT. 
After fasting for 6 hours, FDG 3.5 MBq/kg body weight 
was intravenously injected if the patient’s blood sugar level 
was lower than 200 mg/dl. Image acquisition was started 
60 minutes after the injection by using a single PET/CT 
combined scanner (Eminence-SOPHIA, Shimadzu, Kyoto, 
Japan).6 Image emission data from the eyes to the mid-thigh 
area were continuously acquired over a period of approxi-
mately 20 minutes. After attenuation corrections were made 
for the obtained image data, they were reconstructed using 
a dynamic row-action expectation maximization algorithm.7 
Then, the reconstructed sectional images were evaluated 
visually and quantitatively by using the SUVmax inside a 
volume of interest (VOI) placed on the lesions. SUVmax 
was calculated by: [(maximum activity in VOI)/(volume of 
VOI)]/[(injected FDG dose)/(patient weight)]. The quality of 
radiation measurements of the PET/CT scanner was assured 
by the calibration in accordance with an National Electrical 
Manufacturers Association (NEMA) NU-2 2001 standard.8
Treatment
We have previously reported the details about our SBRT 
technique.9,10 Before 2011, treatment for central and periph-
eral NSCLC was planned to enclose the planning target vol-
ume (PTV) by the 80% isodose-line of the maximum dose 
with a total dose of 40 Gy and 50 Gy in five fractions, which 
was equivalent to the prescribed dose. From 2011, it was by 
the 60% isodose-line with 60 Gy and 50 Gy in five fractions10 
and, for cases where the target lesions were located adjacent 
to a critical organ, such as a main bronchus, pulmonary artery, 
esophagus, or heart, or extensively adhered to chest wall, the 
total dose was reduced by 10 Gy. The dose covering 95% of 
the PTV (D95) was more than or equal to the prescribed dose.9 
In our definition of treatment dose, the biologically effective 
doses assuming α/β ratios of 10 Gy (BED10) for the pre-
scribed doses of 40 Gy, 50 Gy, and 60 Gy in five fractions at 
the PTV surface were 72 Gy_10, 100 Gy_10, and 132 Gy_10, 
respectively, and those at the maximum dose points were 100 
Gy_10, 141 Gy_10, and 300 Gy_10, respectively.
No adjuvant chemotherapy was performed in any patient.
Follow-Up
Our follow-up procedures were previously described in 
detail.11 In brief, all patients were followed up monthly during 
the first 6 months. CT scans were performed at 1 and 3 months 
after SBRT and at 3-month intervals during the first 2 years 
thereafter. Subsequently, follow-up interviews and CT scans 
were obtained at 4- to 6-month intervals. In addition, FDG-
PET and brain magnetic resonance imaging were performed 
1 year after SBRT.
Local recurrence was diagnosed by pathological 
conﬁrmation or an increase of more than 25% in the cross-
sectional tumor size on successive CT scans at least three 
times over a 6-month period. Regional and distant recurrence 
was deﬁned as new appearance of mediastinal or hilar lymph 
node and distant metastasis, respectively. For DFS, only recur-
rence was counted as an event and death from other reasons 
was censored.
Statistical Analysis
The distributions of SUVmax in patients with patholog-
ically and clinically diagnosed NSCLC were compared using 
the Student’s t test. Differences in control and survival rates 
were compared by using Kaplan–Meier curves and log-rank 
tests. The predictive performance of SUVmax was assessed by 
receiver-operating characteristic curves and total area under 
the curve (AUC). Optimal thresholds were determined by cal-
culating minimum balanced error rates. The 95% confidence 
interval for sensitivity, specificity, and AUC were calculated. 
Univariate and multivariate Cox regression analyses were used 
to determine whether any of the clinical or treatment-related 
variables were predictors of local control. Univariate factors 
with p value less than 0.20 were included in the multivariate 
analysis. For all tests, a p value less than 0.05 was considered 
statistically significant. Analyses were performed using IBM 
SPSS Statistics 20.0 (IBM, Inc., Armonk, NY).
RESULTS
Eligible Patients and Those Outcomes
From a total of 283 NSCLC patients treated with SBRT, 
152 patients were eligible for this study (Fig. 1), includ-
ing 90 patients with pathologically proven NSCLC and 62 
patients with clinically diagnosed NSCLC. Among patients 
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with clinically diagnosed NSCLC, SUVmaxs were more than 
2.5 in 42 patients (68%) and tumor marker levels were ele-
vated in 34 patients (55%). Patient characteristics are shown 
in Table 1. Median patient age was 79 years (range, 53–90 
years). The median follow-up period was 25.3 months (range, 
1.3–77.4 months). Three patients died because of causes other 
than NSCLC within 6 months.
On FDG-PET studies, the median SUVmaxs in primary 
tumors of pathologically and clinically diagnosed NSCLC 
were 3.2 (range, 0.7–13.3) and 3.1 (range, 0.7–12.2), respec-
tively; these values were not significantly different (p=0.42). 
Three-year DFS rates for patients with pathologically and 
clinically diagnosed NSCLC were 69.5% and 73.8%, respec-
tively; these rates were also not significantly different (p=0.87; 
Fig. 2). Therefore, we consolidated the data for these patients 
and analyzed them together.
Local, regional nodal, and distant recurrences occurred 
in 14, 11, and 27 patients, respectively. There were 21 cause-
specific deaths and 31 deaths from other reasons.
18F-FDG-PET/CT SUVmax as Predictors  
of Outcome
The median SUVmax of the primary lesion in patients 
with recurrence/death and nonrecurrence/alive, AUC on 
receiver-operating characteristic curves, the optimal thresh-
old SUVmax, and its sensitivity and specificity for outcomes 
are shown in Table 2. Patients with SUVmax less than thresh-
old for local, regional nodal, and distant metastasis controls, 
and for DFS, cancer-specific survival, and OS were signifi-
cantly better than those with SUVmax more than threshold 
(p<0.005). The median blood glucose level (mg/dl) was 97 
(range, 77–192). Only four patients, including three who 
remain alive with no recurrence and one who died from dis-
tant metastasis, had blood sugar levels exceeding 150 mg/dl. 
The patient who died was correctly classified under the poor 
prognosis group.
Figure 3 shows Kaplan–Meier curves for DFS, cancer-
specific survival, and OS divided by the most optimal thresh-
old SUVmax, which were 2.47, 2.55, and 2.55, respectively.
Univariate and Multivariate Analysis 
for Predictors of DFS and OS
The results of univariate and multivariate analyses for 
DFS and OS are shown in Table 3. The univariate analyses 
showed that tumor diameter, T stage, and SUVmax were sig-
nificantly related to DFS, and that body mass index (BMI), 
tumor diameter, T stage, and SUVmax were significantly 
related to OS. Body mass index (BMI), tumor diameter, 
FIGURE 1.  Study flow chart.
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T stage, and SUVmax were significantly related to OS. In 
multivariate analysis, we excluded tumor diameter because 
the correlation coefficient (r) between tumor diameter and T 
stage exceeded 0.9. Multivariate analysis indicated that only 
SUVmax was significantly associated with DFS. BMI, T 
stage, pathological confirmation, and SUVmax were signifi-
cantly related to OS.
DISCUSSION
A meta-analysis conducted by the European Lung 
Cancer Working Party identiﬁed 13 studies examining FDG 
uptake and prognosis for patients with stage I–III NSCLC 
who underwent resection. They found that the hazard of death 
was twice as great in patients with high FDG uptake com-
pared with those with low FDG uptake (hazard ratio 2.09).12 
In addition, another systematic review of patients with stage 
I NSCLC also suggested that higher FDG uptake was asso-
ciated with worse DFS and OS.3 Across studies, the median 
DFS or OS was 70% for patients with higher FDG uptake 
compared with 88% for patients with lower FDG uptake.3 
FDG uptake has the potential to be used as a biomarker for 
identifying stage I patients who are at increased risk of death 
or recurrence and therefore could identify candidates for par-
ticipation in future trials of adjuvant therapy.
For SBRT, only a few reports with relatively small num-
bers of patients have evaluated FDG uptake as a potential 
biomarker. The utility of FDG uptake as a biomarker remains 
controversial. However, two studies positively associated FDG 
uptake with survival by multivariate analysis: Chang et al.13 
reported that SUVmax was the only predictor for OS, with 
a hazard ratio of 2.15 divided at the median SUVmax, and 
Clarke et al.14 also reported SUVmax as the only predictor 
for DFS. Meanwhile, two univariate analysis studies failed to 
establish a significant association between FDG uptake and 
survival.15,16
In the present study, we clearly demonstrated that 
SUVmax was a strong predictor for all outcomes, including 
control of local, regional nodal, and distant metastasis, DFS, 
and OS. By multivariate analysis, SUVmax as well as T stage 
were independent predictors for OS. The two factors seemed 
to influence cancer-specific survival. Other factors associated 
with OS included BMI and pathological confirmation. They 
also seemed to influence death from other causes, because both 
factors were not predictors of DFS, even by univariate analy-
sis. NSCLC patients often have emphysema as a comorbidity, 
and low BMI was correlated with short OS in patients with 
emphysema.17 Patients with clinically diagnosed NSCLC might 
include benign other disease than NSCLC and have better out-
comes. In addition, the pathological diagnosis of ground-glass 
opacities was not often established although most of the cases 
were likely to be bronchoalveolar carcinoma. It was reported 
that their SUVmaxs were as low as a median value of 0.6 and 
they showed better outcomes.18 and have better outcomes. 
Therefore, we at first demonstrated that there was no signifi-
cant difference in distribution of SUVmax (p=0.42) and DFS 
(p=0.87; Fig. 2) between patients with pathologically and clini-
cally diagnosed NSCLC. However, lack of pathological confir-
mation was a worse predictor of OS, as was shown in a German 
multicenter analysis.19 It might indicate patients’ inactive per-
formance status or comorbid disease, because physicians might 
hesitate to perform an invasive biopsy in such patients.
On the basis of these results, we suggest the use of more 
intensive treatment for medically inoperable stage I NSCLC. 
FIGURE 2.  Disease-free survival rates of candidate patients 
with and without pathological confirmation. There is no dif-
ference in disease-free survival rates between patients with 
and without pathological confirmation of non–small-cell lung 
cancer (p=0.87).
TABLE 1.  Patient and Tumor Characteristics
Characteristic n
Median age (range), yrs 79 (53–90)
Sex: male/female 109/43
Median SUVmax (range) 3.2 (0.7–13.3)
Median follow-up duration (range), months 25.3 (1.3–77.4)
BMI (range) 21.1 (12.7–37.6)
Operability: yes/no 39/113
Median maximum tumor diameter (range), cm 2.5 (1.0–6.2)
T stage:a T1a/ T1b / T2 56/53/43
Pathology
  Pathology-proven NSCLC
  Adenocarcinoma 52
  Squamous cell carcinoma 28
  Unclassified NSCLC 10
Pathologically unproven 62
  Tumor opacity
  Solid 130
  GGO 6
  GGO with solid 16
Location: central/peripheral 41/111
Total dose: 40 Gy/50 Gy/60 Gy 26/106/20
SUVmax, the maximum standardized uptake value; BMI, body mass index; NSCLC, 
non–small-cell lung cancer; GGO, ground-glass opacity.
aAll patients were stage N0,M0.
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First, to improve local control, dose escalation might be 
required. A large single-institution series suggested a posi-
tive dose-control relationship for SBRT.20 Another single-
institution series suggested that the local control rate could 
be improved by securing the minimum dose for PTV.21 In the 
German multicenter analysis, multivariate analysis revealed 
that PTV-encompassing dose was a significant factor for local 
control and OS. This result indicated that intensified SBRT 
with the consequence of improved local tumor control trans-
fers into improved OS.19 Second, we should seek optimal treat-
ment to decrease regional node and distant metastasis, which 
are the main causes of cancer death after SBRT.22 SBRT can-
didates are medically inoperable, elderly and/or with comor-
bidities. For such patients, it is doubtful whether systemic 
chemotherapy would prolong OS. However, for completely 
resected stage IB NSCLC patients, systemic chemotherapy 
with uracil-tegafur significantly increased OS rate.23 Although 
the role of platinum-based adjuvant chemotherapy in patients 
with stage IB has not been established, further randomized 
trials for select patients are required using biological mark-
ers.24 Recently, combination chemo-radiotherapy was reported 
to provide a clinically signiﬁcant beneﬁt over radiother-
apy alone in a select group of elderly patients with locally 
advanced NSCLC.25 Therefore, mild systemic chemotherapy 
might have a potential role in patients with a high SUVmax 
and relatively good performance status.
SUVmax is an index that can be obtained by rather sim-
ple calculations. Therefore, based on the results of the pres-
ent study, we can insist that oncologists should more actively 
use 18F-FDG-PET/CT testing and calculate the SUVmax of 
lesions in clinical practice of SBRT for early-stage NSCLC. 
As a result, SUVmax would be a popular imaging biomarker 
for patients with this disease. However, SUV is not an abso-
lutely reliable quantitative index. For example, it is reported 
that obtained SUVmaxs depend on the imaging protocols and 
scanners used,26 uptake time27 and respiratory motion espe-
cially in studies about lung cancer.28 Therefore, it is not suit-
able to directly apply our results to other institutes. To use 
TABLE 2.  Relationships between the Maximum Standardized Uptake Value and Clinical Outcomes
SUVmax SUVmax p Value
< Threshold > Threshold
Local control, n 78 74
  AUC (95% CI) 0.78 (0.66–0.91) <0.001
  Threshold SUVmax 3.35
  Sensitivity/specificity 0.93/0.56
  3-yr local control rate 97.7% 71.5% <0.001
Regional control, n 90 62
  AUC (95% CI) 0.78 (0.67–0.89) 0.002
  Threshold SUVmax 3.64
  Sensitivity/specificity 0.91 0.63
  3-yr regional control rate 98.6% 78.6% <0.001
Distant metastasis control, n 59 93
  AUC (95% CI) 0.58 (0.48–0.69) 0.18
  Threshold SUVmax 2.47
  Sensitivity/specificity 0.85/0.44
  3-yr distant metastasis– free rate 96.0% 66.7% 0.002
Disease-free survival, n 59 93
  AUC (95% CI) 0.68 (0.58–0.77) 0.001
  Threshold SUVmax 2.47
  Sensitivity/specificity 0.89/0.47
  3-yr disease-free survival rate 93.0% 58.3% <0.001
Cancer-specific survival, n 60 92
  AUC (95% CI) 0.68 (0.58–0.79) 0.01
  Threshold SUVmax 2.55
  Sensitivity/specificity 0.95/0.45
  3-yr cancer-specific survival rate 100% 61.5% <0.001
Overall survival, n 60 92
  AUC (95% CI) 0.71 (0.62–0.79) <0.001
  Threshold SUVmax 2.55
  Sensitivity/specificity 0.85/0.52
  3-yr overall survival rate 86.5% 42.2% <0.001
SUVmax, maximum standardized uptake value; AUC, area under the curve on receiver-operating characteristic curves; CI, confidence interval.
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FIGURE 3.  Clinical outcomes of patients divided by each threshold maximum standardized uptake value. Kaplan–Meier curves 
show that all the outcomes of patients with an SUVmax lower than the threshold value are significantly better than those with 
higher SUVmax. A, Local control rate, (B) regional node control rate, (C), distant metastasis–free rate, (D) disease-free survival 
rate, (E) cancer-specific survival rate, and (F) overall survival rate.
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TABLE 3.  Univariate and Multivariate Analysis for Disease-Free and Overall Survival
Characteristic
Disease-Free Survival Overall Survival
HR 95% CI  p Value HR 95% CI p Value
Univariate analysis
  Age 1.04 0.99–1.10 0.16 1.04 1.00–1.09 0.08
  Sex 0.41 0.24
   Male (n=109) 1.00 1.00
   Female (n=43) 0.74 0.37–1.50 0.67 0.34–1.31
  BMI 0.99 0.89–1.09 0.75 0.90 0.8–0.99 0.02* 
  Operability 0.27 0.19
   Yes (n=37) 1.00 1.00
   No (n=105) 0.65 0.68–3.97 1.58 0.79–3.16
  Maximum diameter 1.98 1.45–2.69 <0.01* 1.45 1.11–1.90 <0.01* 
  T stage 0.01* 0.01* 
   T1a (n=56) 1.00 1.00
   T1b (n=53) 3.90 1.52–10.0 <0.01* 2.78 1.40–5.52 <0.01* 
   T2 (n=43) 3.70 1.40–9.75 <0.01* 2.10 1.01–4.40 0.05
  Location 0.28 0.71
   Peripheral (n=104) 1.00 1.00
   Central (n=38) 1.47 0.73–2.97 1.13 0.61–2.09
  Total dose 0.21 0.58
   40 Gy (n=23) 1.00 1.00
   50 Gy (n=119) 0.50 0.23–1.08 0.08 0.70 0.35–1.41 0.32
   60 Gy (n=23) 0.68 0.18–2.54 0.62 0.13–2.88 0.54
  Pathologically proven 0.87 0.08
   Yes (n=90) 1.00 1.00
   No (n=62) 0.95 0.48–1.86 1.64 0.95–2.83
  Pathology 0.42 0.23
      Adenocarcinoma (n=52) 1.00 1.00
   SCC (n=28) 1.92 0.74–4.97 0.18 1.67 0.70–3.98 0.25
   NOS (n=10) 2.32 0.71–7.53 0.16 1.58 0.51–4.91 0.43
   Unproven (n=62) 1.33 0.58–3.08 0.50 2.06 1.04–4.08 0.04* 
  Tumor opacity 0.08 0.02*
   Solid (n=130) 1.00 1.00
   GGO (with solid) (n=22) 0.28 0.07–1.16 0.19 0.05–0.78
  SUVmax <0.01* <0.01* 
    <Thresholda (n=59, 60) 1.00 1.00
    >Thresholda (n=93, 92) 6.25 2.20–17.732 4.18 1.97–8.87 <0.01* 
Multivariate analysis
  Age 1.02 0.96–1.08 0.57 1.03 0.98–1.08 0.26
  BMI 0.92 0.85–0.99 0.04* 
  Operability 0.34
   Yes (n=37) 1.00
   No (n=105) 1.26 0.61–2.63
  T stage 0.06 0.04* 
   (n=56) 1.00 1.00
   T1b (n=53) 2.80 1.07–7.28 0.04* 2.54 1.24-5.22 0.01* 
   T2 (n=43) 3.16 1.17–8.54 0.02* 2.01 0.93-4.33 0.08
  Pathological confirmation 0.04* 
   Yes (n=90) 1.00
   No (n=62) 1.83 1.03–3.26
  Tumor opacity 0.74 0.36
   Solid (n=130) 1.00 1.00
(Continued)
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SUVmax as a reliable biomarker in clinical practice in many 
institutions, researchers in the field of nuclear medicine are 
making efforts for the standardization procedures.29 For exam-
ple, European Association of Nuclear Medicine published 
a guideline to facilitate the standardization of tumor PET 
imaging30 and European Association of Nuclear Medicine 
Research Ltd. started a program to accredit imaging sites that 
meet these standard requirements. Similar projects are also 
planned in other areas.31 In the future, the issue of interinstitu-
tional differences would be improved.
Limitations
This study had several limitations, including a short 
follow-up period, limited sample size, and its retrospec-
tive nature. In this study, 39.5% of tumors were not patho-
logically confirmed. Reasons for the lack of pathology data 
included negative biopsy studies and the inability to perform 
biopsies because of medical comorbidities or patient refusal. 
Accordingly, pathological nonconfirmation was one of the 
worse predictors for OS. However, other studies have also 
reported the results of SBRT after obtaining 31% to 51% 
pathologic confirmation of malignancy.32,33 In addition, the 
treatment outcomes of patients diagnosed with NSCLC with 
no pathological confirmation were almost identical to those of 
patients with pathological confirmation.34,35
CONCLUSIONS
In conclusion, multivariate analysis revealed that the 
SUVmax of a primary tumor was the only prognostic factor 
for DFS, and that it was the strongest prognostic factor for OS 
in addition to BMI, T stage, and pathological confirmation. 
Further studies are required to ascertain whether SUVmax 
might have an impact on changing treatment strategies, 
including dose escalation and adjuvant therapies, and, accord-
ingly, on improving patient outcomes.
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